Dr. Moser is an oncologist who has worked as a clinician and academic researcher for over 20 years and specialized in drug development for the past 10. She completed her PhD in Statistics working at the EORTC in Brussels and has led many multi-institutional trials and related cancer survivorship projects since. After completing her MBA at MIT Sloan School of Management (2017), she moved to the US and shifted focus from academic to commercial research. She has helped drive the clinical pipeline from early to late stage in larger (Elekta, Roche) and smaller (Augmenix, Kaiku, Artidis, Galera Therapeutics) companies and commercialization of several products including the post-marketing performance. Dr. Moser has obtained extensive clinical operational and regulatory experience dealing with different stakeholders (academic, industry, policymakers and patient advocates) and helped direct the investment in private owned drug-development, as well as new cancer centers worldwide and was instrumental in launching Portugal’s National Cancer Institute. Dr. Moser previously served as the Vice President for Clinical Development for Galera Therapeutics, with who she went IPO in 2019 and SVP Clinical Strategy for ELEKTA Inc, a global radiation oncology device vendor (2017-2018). She founded Nanocan Therapeutics Corporation in 2020, served as their Chief Scientific Officer and heads their Scientific Advisory Board. She currently holds the position of Chief Medical Officer at DEKA Biosciences Inc, using here expertise and network to drive fast clinical translation of innovative, more effective, and better tolerated immunotherapies.
